Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon
This paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon. Questionnaires were used to evaluate willingness to pay, and patients who could still afford their medication 6 months after the sur...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2004-08-01
|
| Series: | SAHARA-J |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/17290376.2004.9724833 |
| _version_ | 1828349603684024320 |
|---|---|
| author | Kenneth Ngwambokong Muko Valentine Che Ngwa Leslie Chigang Igbinosum Gladys Ngwa Anke Meiburg Elvis Neba Shu |
| author_facet | Kenneth Ngwambokong Muko Valentine Che Ngwa Leslie Chigang Igbinosum Gladys Ngwa Anke Meiburg Elvis Neba Shu |
| author_sort | Kenneth Ngwambokong Muko |
| collection | DOAJ |
| description | This paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon. Questionnaires were used to evaluate willingness to pay, and patients who could still afford their medication 6 months after the survey were also investigated, to give an indication of actual ability to pay. In addition, oral interviews were carried out for clarification. In all, 84 patients out of a total of 186 were involved in the study. Results indicated that more men (39%) were willing to pay than women (22%), although more women (56%) were afflicted than men. Willingness to pay was directly dependent on cost with 69%, 22% and 9% of respondents indicating willingness to pay $1, $2 and $3 a day respectively. After 6 months of treatment, 22% of patients were still on therapy. A majority of patients stopped taking the drugs after 6 months due to financial constraints. Apart from cost, stigma, disbelief and side-effects of medication were found to be the main factors militating against willingness to pay. Improved counselling and provision of information, reduced cost of drugs including laboratory tests, and destigmatisation programmes are recommended to improve patients' ability to pay for antiretrovirals. |
| first_indexed | 2024-04-14T01:12:04Z |
| format | Article |
| id | doaj.art-4c6bd618e9b14fbdbfeea91ad9e5db0d |
| institution | Directory Open Access Journal |
| issn | 1729-0376 1813-4424 |
| language | English |
| last_indexed | 2024-04-14T01:12:04Z |
| publishDate | 2004-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | SAHARA-J |
| spelling | doaj.art-4c6bd618e9b14fbdbfeea91ad9e5db0d2022-12-22T02:20:59ZengTaylor & Francis GroupSAHARA-J1729-03761813-44242004-08-011210711310.1080/17290376.2004.9724833Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in CameroonKenneth Ngwambokong Muko0Valentine Che Ngwa1Leslie Chigang2Igbinosum Gladys Ngwa3Anke Meiburg4Elvis Neba Shu5Catholic Health Service of the archdiocese of Bamenda, CameroonSt James University Hospital, Leeds, UKSt Louis Clinic Bamenda, CameroonSt Martin De Porres HospitalSt Martin De Porres Hospital, NjinikomDepartment of pharmacology, College of Medicine, University of Nigeria NsukkaThis paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon. Questionnaires were used to evaluate willingness to pay, and patients who could still afford their medication 6 months after the survey were also investigated, to give an indication of actual ability to pay. In addition, oral interviews were carried out for clarification. In all, 84 patients out of a total of 186 were involved in the study. Results indicated that more men (39%) were willing to pay than women (22%), although more women (56%) were afflicted than men. Willingness to pay was directly dependent on cost with 69%, 22% and 9% of respondents indicating willingness to pay $1, $2 and $3 a day respectively. After 6 months of treatment, 22% of patients were still on therapy. A majority of patients stopped taking the drugs after 6 months due to financial constraints. Apart from cost, stigma, disbelief and side-effects of medication were found to be the main factors militating against willingness to pay. Improved counselling and provision of information, reduced cost of drugs including laboratory tests, and destigmatisation programmes are recommended to improve patients' ability to pay for antiretrovirals.https://www.tandfonline.com/doi/10.1080/17290376.2004.9724833HIV/AIDStreatmentaccess to antiretroviralsdrug costsaffordabilityle VIH/SIDA |
| spellingShingle | Kenneth Ngwambokong Muko Valentine Che Ngwa Leslie Chigang Igbinosum Gladys Ngwa Anke Meiburg Elvis Neba Shu Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon SAHARA-J HIV/AIDS treatment access to antiretrovirals drug costs affordability le VIH/SIDA |
| title | Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon |
| title_full | Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon |
| title_fullStr | Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon |
| title_full_unstemmed | Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon |
| title_short | Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon |
| title_sort | willingness to pay for treatment with highly active antiretroviral haart drugs a rural case study in cameroon |
| topic | HIV/AIDS treatment access to antiretrovirals drug costs affordability le VIH/SIDA |
| url | https://www.tandfonline.com/doi/10.1080/17290376.2004.9724833 |
| work_keys_str_mv | AT kennethngwambokongmuko willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon AT valentinechengwa willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon AT lesliechigang willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon AT igbinosumgladysngwa willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon AT ankemeiburg willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon AT elvisnebashu willingnesstopayfortreatmentwithhighlyactiveantiretroviralhaartdrugsaruralcasestudyincameroon |